2026 Oncology Pipeline Trends: What the Data Shows About Where Pharma Is Betting
life sciences competitive intelligence

2026 Oncology Pipeline Trends: What the Data Shows About Where Pharma Is Betting

Srinivas Padmanabharao

Author

Srinivas Padmanabharao

Published : 01 Oct 2026

Key Takeaways :

Oncology pipeline trends in 2026 highlight growing competition across antibody-drug conjugates, bispecific antibodies, cell therapies, radiopharmaceuticals and cancer vaccines. With more than 30,500 oncology assets in development, pharmaceutical companies must prioritise differentiated targets, promising modalities and commercially viable indications. AI-powered competitive intelligence can help teams track clinical trials, analyse emerging technologies, monitor deal activity and identify strategic opportunities across an increasingly crowded oncology landscape.

Frequently Asked Questions

References

[1] Beacon Intelligence. The Oncology H1 2026 Landscape Review. The report describes the H1 2026 oncology drug, trial, commercial, and regulatory landscape and reports more than 30,500 oncology assets alongside accelerating trial activity.

[2] IQVIA Institute. Oncology Innovation: 2026 and Beyond and Global Oncology Trends 2025. IQVIA reports that oncology remained the largest pharmaceutical market, with 2025 oncology spending estimated at $291 billion and continued strong growth expected through 2030. It also highlights major oncology M&A activity and increasing competitive density.

[3] Beacon Intelligence. The ADC H1 2026 Landscape Review. The review reports 2,689 ADC assets, 3,397 trials, $26 billion in deal value, and continued expansion of next-generation ADC approaches.

[4] Yao G, Shi L, Zheng Y. The landscape of innovative oncology drug targets. Drug Discovery Today. 2026;31(1):104571. The analysis examines 5,127 oncology drugs across 1,603 targets and identifies trends in target validation, modalities, dual-target strategies, and geographic development.

[5] Marshall A. The year of the bispecific in oncology and beyond. Nature Biopharma Dealmakers. December 2025. The article examines the growing role of bispecific antibodies in biopharma licensing and the increasing participation of Chinese biotechnology companies in antibody engineering and oncology development.

Connect With Us

Related Posts